Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices traded up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 191 points (1.1%) at 17,512 as of Friday, Jan. 16, 2015, 4:20 PM ET. The NYSE advances/declines ratio sits at 2,533 issues advancing vs. 578 declining with 102 unchanged.

The Drugs industry as a whole closed the day up 2.1% versus the S&P 500, which was up 1.3%. Top gainers within the Drugs industry included

ImmuCell

(

ICCC

), up 5.5%,

Aoxing Pharmaceutical

(

AXN

), up 11.7%,

Tianyin Pharmaceutical

TheStreet Recommends

(

TPI

), up 11.1%,

Aurinia Pharmaceuticals

(

AUPH

), up 2.1% and

Ruthigen

(

RTGN

), up 5.2%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Ruthigen

(

RTGN

) is one of the companies that pushed the Drugs industry higher today. Ruthigen was up $0.19 (5.2%) to $3.86 on light volume. Throughout the day, 3,776 shares of Ruthigen exchanged hands as compared to its average daily volume of 16,800 shares. The stock ranged in a price between $3.57-$4.13 after having opened the day at $3.57 as compared to the previous trading day's close of $3.67.

Ruthigen has a market cap of $17.7 million and is part of the health care sector. Shares are up 4.9% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close,

Aurinia Pharmaceuticals

(

AUPH

) was up $0.08 (2.1%) to $3.69 on average volume. Throughout the day, 19,680 shares of Aurinia Pharmaceuticals exchanged hands as compared to its average daily volume of 16,900 shares. The stock ranged in a price between $3.56-$3.70 after having opened the day at $3.61 as compared to the previous trading day's close of $3.62.

Aurinia Pharmaceuticals has a market cap of $114.0 million and is part of the health care sector. Shares are down 0.7% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Aoxing Pharmaceutical

(

AXN

) was another company that pushed the Drugs industry higher today. Aoxing Pharmaceutical was up $0.04 (11.7%) to $0.34 on light volume. Throughout the day, 11,022 shares of Aoxing Pharmaceutical exchanged hands as compared to its average daily volume of 75,600 shares. The stock ranged in a price between $0.31-$0.34 after having opened the day at $0.31 as compared to the previous trading day's close of $0.30.

Aoxing Pharmaceutical Company, Inc., a specialty pharmaceutical company, researches, develops, manufactures, and distributes various narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. Aoxing Pharmaceutical has a market cap of $20.5 million and is part of the health care sector. Shares are down 2.4% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate Aoxing Pharmaceutical a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Aoxing Pharmaceutical as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk and weak operating cash flow.

Highlights from TheStreet Ratings analysis on AXN go as follows:

  • The debt-to-equity ratio is very high at 14.68 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Along with this, the company manages to maintain a quick ratio of 0.19, which clearly demonstrates the inability to cover short-term cash needs.
  • Net operating cash flow has declined marginally to -$2.29 million or 2.78% when compared to the same quarter last year. Despite a decrease in cash flow AOXING PHARMACEUTICAL CO INC is still fairing well by exceeding its industry average cash flow growth rate of -19.42%.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, AOXING PHARMACEUTICAL CO INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for AOXING PHARMACEUTICAL CO INC is currently very high, coming in at 72.68%. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -0.17% is in-line with the industry average.
  • This stock has increased by 43.47% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the future course of this stock, we feel that the risks involved in investing in AXN do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.

You can view the full analysis from the report here:

Aoxing Pharmaceutical Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.